The Tisch Cancer Institute at Mount Sinai | Strategic Alliance Partners

February 06, 2020

Deepu Madduri, MD, discusses the results of the CARTITUDE-1 trial and the next phase of development with JNJ-4528.

January 30, 2020

William K. Oh, MD, discusses the phase III ENZAMET trial in metastatic hormone-sensitive prostate cancer.

January 29, 2020

Marina Kremyanskaya, MD, discusses the effect of CPI-0610 in patients with myelofibrosis.

January 14, 2020

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.

December 12, 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

December 07, 2019

William K. Oh, MD, discusses remaining challenges in metastatic hormone-sensitive prostate cancer.

November 26, 2019

Ajai Chari, MD, discusses the implementing quadruplet-regimens in transplant-eligible multiple myeloma.

November 21, 2019

Ajai Chari, MD, discusses transplant eligibility in multiple myeloma.

November 18, 2019

Ibrahim S. Alshaygy, MD, MSC, discusses research suggesting a smaller surgical resection margin for dermatofibrosarcoma protuberans.

November 14, 2019

We sat down with Ajai Chari, MD, and Sundar Jagannath, MD, both of Mount Sinai Hospital, to provide insight on controversial, but critical, questions regarding the merits of quadruplet versus triplet therapy in the newly diagnosed setting, the optimal maintenance approach in high-risk patients, and the data in support of and against initiating treatment in patients with smoldering multiple myeloma.

October 25, 2019

Hearn Jay Cho, MD, PhD, discusses investigational bispecific T-cell engager therapies in multiple myeloma.

September 20, 2019

Samir Parekh, MBBS, discusses using genomics to treat patients with multiple myeloma.

September 04, 2019

We traveled to New York City, New York, for a State of the Science Summit™ on Multiple Myeloma, which featured insights from the faculty from the Mount Sinai Hospital.

August 30, 2019

Samir Parekh, MBBS, highlights ongoing research regarding personalized medicine for multiple myeloma.

August 28, 2019

Sundar Jagannath, MD, highlights the current state of the relapsed/refractory multiple myeloma paradigm and research regarding next steps for advancing treatment.

August 08, 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the use of frontline daratumumab (Darzalex) in transplant-eligible patients with multiple myeloma.

August 06, 2019

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, The Tisch Cancer Institute, Mount Sinai Hospital, discusses results from the HCRN GU14-182 study, which examined maintenance pembrolizumab versus placebo in patients with metastatic urothelial cancer.

August 06, 2019

Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.

August 03, 2019

Deepu Madduri, MD, assistant professor, medicine, hematology and medical oncology, Mount Sinai Hospital, discusses the potential impact of CAR T-cell therapy in multiple myeloma.

July 29, 2019

Ajai Chari, MD, associate professor, hematology and medical oncology, Mount Sinai Hospital, discusses the phase III E3A06 study, which looked at the effects of lenalidomide in patients with smoldering myeloma.